KLHL38 Antibody

Introduction to KLHL38 Antibody

KLHL38 antibodies are polyclonal reagents primarily used to investigate the biological roles of the KLHL38 protein, which regulates protein turnover, cytoskeletal dynamics, and cellular processes like proliferation and migration . These antibodies enable researchers to visualize KLHL38 expression in tissues and cell lines, particularly in cancer research, where KLHL38 has emerged as a biomarker and therapeutic target .

Validation and Quality Control

• Specificity: Validated via IHC in human thyroid, prostate cancer, and NSCLC tissues .

• Functional Assays: Confirmed in studies showing KLHL38’s role in PTEN ubiquitination and Akt pathway activation .

Role in Non-Small Cell Lung Cancer (NSCLC)

• Overexpression: KLHL38 is significantly upregulated in NSCLC tissues compared to normal samples (P < 0.001) .

• Clinical Correlations: High KLHL38 levels correlate with:

  • Larger tumor size (P = 0.000)

  • Lymph node metastasis (P = 0.000)

  • Advanced TNM stage (P = 0.000) .

• Mechanistic Insights:

  • Promotes PTEN ubiquitination, leading to Akt signaling activation .

  • Enhances proliferation via upregulation of cyclin D1, cyclin B, and c-Myc, while suppressing p21 .

  • Drives metastasis by increasing RhoA/MMP9 and reducing E-cadherin .

In Vivo Evidence

• Mouse Models: KLHL38 overexpression in A549 and SK-MES-1 cells increased xenograft tumor growth and lung metastasis rates (5/5 vs. 1/5 in controls) .

Therapeutic Implications

KLHL38’s interaction with PTEN and its downstream effects on Akt signaling position it as a potential:

• Prognostic Biomarker: High expression predicts poor survival in NSCLC patients .

• Therapeutic Target: Inhibiting KLHL38 could suppress tumor progression by stabilizing PTEN and blocking Akt activation .

Limitations and Future Directions

• Validation Discrepancies: TCGA data conflicts with clinical findings on KLHL38’s prognostic value in lung adenocarcinoma .

• Research Gaps: Mechanisms linking KLHL38 to other cancers (e.g., neurodegenerative disorders) remain unexplored .